A compounded form of imiquimod, a topical immune response modifier, showed promise as a treatment for ocular surface ...

Ocular Therapeutix (OCUL) announced that the first patient has been randomized in the HELIOS-3 Phase 3 registrational program for AXPAXLI for the ...

Diabetic retinopathy is a complication of diabetes that affects the back of the eye and can cause vision loss, blurry vision ...

Eye injections are the only medication currently available to treat diabetes-related retinopathy. Modern eye injections are not painful and don’t cause many side effects. Diabetic retinopathy affects ...

Retinopathy refers to conditions or damage affecting the retina. Without treatment, it can cause blindness. Hypertensive retinopathy results from high blood pressure, while diabetic retinopathy is a ...

The race to develop safer, longer lasting, and less invasive treatments is accelerating, and at the heart of that challenge lies drug delivery.

Diabetic retinopathy is a complication of diabetes that affects vision. Nonproliferative diabetic retinopathy describes the earlier stages of the condition before it progresses into the final and most ...

While rapid weight-loss with bariatric surgery or drugs might temporarily worsen diabetic retinopathy as blood sugar levels are rapidly corrected, the low overall risk likely doesn't outweigh the ...

Proliferative diabetic retinopathy (PDR) is the advanced stage of diabetic retinopathy. It involves the development of abnormal retinal blood vessels. The vessels may leak blood and fluid into the ...

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative ...